Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-nCoV/index.html

Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States

Filetype[PDF-3.79 MB]


English
Details Supporting Files You May Also Like

Details:

  • Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.)
  • Description:
    COVID-19 vaccination is recommended for everyone aged 12 years and older for the prevention of coronavirus disease 2019 (COVID-19) in the United States under the FDA Emergency Use Authorization (EUA). The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of:

    • Pfizer-BioNTech COVID-19 vaccine (in persons aged 12–15 years and aged ≥16 years)

    • Moderna COVID-19 vaccine (in persons aged ≥18 years)

    • Janssen (Johnson & Johnson) COVID-19 vaccine (in persons aged ≥18 years)

  • Content Notes:
    Background -- Authorized age groups for COVID-19 vaccination -- COVID-19 vaccine administration -- Interchangeability of COVID-19 vaccine products -- People vaccinated for COVID-19 outside the United States -- Coadministration of COVID-19 vaccines with other vaccines -- COVID-19 vaccination and SARS-CoV-2 infection -- Antiviral therapy and COVID-19 vaccination -- Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks -- Considerations for use of an additional dose of COVID-19 vaccine following a primary vaccine series -- Considerations for use of an additional mRNA COVID-19 vaccine dose after an initial 2-dose COVID-19 mRNA vaccine series for immunocompromised people -- Considerations for vaccination of people with certain underlying medical conditions -- Considerations for use of the Janssen COVID-19 vaccine in certain populations -- Considerations involving pregnancy, lactation, and fertility -- Vaccination of children and adolescents -- Patient counseling -- Contraindications and precautions -- Reporting of vaccine adverse events -- Laboratory testing -- Appendix A. Vaccine administration errors and deviations -- Appendix B: Triage of people presenting for COVID-19 vaccination -- Appendix C: Ingredients included in COVID-19 vaccines -- Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination -- References -- Previous Updates.
  • Subjects:
  • Document Type:
    Webpage
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov